IVZ Stock Analysis: | NYSE

Asset Management | NYSE, USA | Market Cap: 14.508m USD | 12M Return: 55.5% | BMG491BT1088 | Charts, Fundamentals & Technical Analysis

Asset Management, Mutual Funds, Exchange-Traded Funds, Alternative Investments
Total Rating 56
Safety 67
Buy Signal 0.77
Asset Management
Industry Rotation: +3.0
Market Cap: 14.5B
Avg Turnover: 122M
Risk 3d forecast
Volatility33.9%
VaR 5th Pctl5.85%
VaR vs Median4.80%
Reward TTM
Sharpe Ratio1.32
Rel. Str. IBD85.4
Rel. Str. Peer Group89.1
Character TTM
Beta1.836
Beta Downside1.724
Hurst Exponent0.407
Drawdowns 3y
Max DD36.52%
CAGR/Max DD0.94
CAGR/Mean DD3.93
EPS (Earnings per Share) EPS (Earnings per Share) of IVZ over the last years for every Quarter: "2021-09": 0.77, "2021-12": 0.86, "2022-03": 0.56, "2022-06": 0.39, "2022-09": 0.34, "2022-12": 0.39, "2023-03": 0.38, "2023-06": 0.31, "2023-09": 0.35, "2023-12": 0.47, "2024-03": 0.33, "2024-06": 0.43, "2024-09": 0.44, "2024-12": 0.52, "2025-03": 0.44, "2025-06": 0.36, "2025-09": 0.61, "2025-12": 0.62, "2026-03": 0.57, "2026-06": 0.71,
EPS CAGR: 19.84%
EPS Trend: 96.6%
Last SUE: 0.64
Qual. Beats: 0
Revenue Revenue of IVZ over the last years for every Quarter: 2021-09: 1750, 2021-12: 1763.4, 2022-03: 1629.4, 2022-06: 1530.4, 2022-09: 1445.7, 2022-12: 1443.4, 2023-03: 1418.2, 2023-06: 1442.8, 2023-09: 1442, 2023-12: 1413.4, 2024-03: 1475.3, 2024-06: 1483.3, 2024-09: 1515.4, 2024-12: 1593, 2025-03: 1529.2, 2025-06: 1515.5, 2025-09: 1640.4, 2025-12: 1692, 2026-03: 1744.5, 2026-06: 1825.6,
Rev. CAGR: 6.53%
Rev. Trend: 96.3%
Last SUE: 0.84
Qual. Beats: 0

Warnings

Fakeout

Tailwinds

Rs Leader
Confidence
Avwap Ph Week

Seasonality 11.6 years of data

Jan -2.5% 19
Feb -6.2% 26
Mar -1.6% 8
Apr -0.7% 7
May -1.3% 2
Jun -1.4% 8
Jul +3.0% 24
Aug -2.6% 16
Sep -0.7% 16
Oct -1.3% 28
Nov +4.0% 26
Dec -1.4% 26

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IVZ

Invesco Ltd. (NYSE: IVZ) is a publicly traded, independent investment management firm headquartered in Atlanta, Georgia, with operations spanning North America, Europe, Asia, and Africa. Founded in 1935 and listed since 1995, the firm provides actively managed investment solutions to a broad client base, including retail investors, institutional clients, high-net-worth individuals, corporations, pension funds, endowments, foundations, sovereign wealth funds, and public entities. It operates within the GICS Asset Management & Custody Banks sub-industry, where peers typically compete on performance, scale, and distribution reach.

The firm offers a diversified product platform spanning equity, fixed income, multi-asset, balanced, and commodity mutual funds, alongside a comparable lineup of exchange-traded funds (ETFs), which are listed instruments that trade on exchanges throughout the trading day. It also manages private funds and separate client-focused equity and fixed income portfolios, investing across public global markets as well as alternatives such as commodities and currencies. Equity portfolios cover growth and value styles across large-, mid-, and small-cap companies, while fixed income mandates include government, municipal, and treasury securities, convertibles, investment-grade and high-yield bonds, senior secured loans, and structured products such as asset-backed, mortgage-backed, and commercial mortgage-backed securities. Investment approaches combine absolute return, global macro, long/short, and quantitative strategies, reflecting the multi-strategy model common among large diversified asset managers.

Headlines to Watch Out For
  • QQQ ETF inflows boost fee revenue on tech rally
  • Active equity outflows continue as investors shift to passive
  • Money market fund AUM surges with higher interest rates
  • Operating margin expands from cost restructuring program
Piotroski VR-10 (Strict) 4.0
Net Income: -64.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.95 > 1.0
NWC/Revenue: -10.26% < 20% (prev 18.90%; Δ -29.16% < -1%)
CFO/TA 0.07 > 3% & CFO 2.01b > Net Income -64.5m
Net Debt (8.82b) to EBITDA (1.49b): 5.93 < 3
Current Ratio: 0.71 > 1.5 & < 3
Outstanding Shares: last quarter (454.4m) vs 12m ago 0.13% < -2%
Gross Margin: 67.42% > 18% (prev 33.37%; Δ 34.06% > 0.5%)
Asset Turnover: 24.66% > 50% (prev 21.59%; Δ 3.07% > 0%)
Interest Coverage Ratio: -4.10 > 6 (EBIT TTM -396.3m / Interest Expense TTM 96.6m)
Altman Z'' 1.39
A: -0.03 (Total Current Assets 1.72b - Total Current Liabilities 2.43b) / Total Assets 27.5b
B: 0.23 (Retained Earnings 6.27b / Total Assets 27.5b)
C: -0.01 (EBIT TTM -396.3m / Avg Total Assets 28.0b)
D: 0.87 (Book Value of Equity 12.5b / Total Liabilities 14.4b)
Altman-Z'' = 1.39 = BB
Beneish M -3.67
DSRI: 0.65 (Receivables 805.5m/1.10b, Revenue 6.90b/6.15b)
GMI: 0.49 (GM 33.37% / 67.42%)
AQI: 1.03 (AQ_t 0.92 / AQ_t-1 0.89)
SGI: 1.12 (Revenue 6.90b / 6.15b)
TATA: -0.08 (NI -64.5m - CFO 2.01b) / TA 27.5b)
Beneish M = -3.67 (Cap -4..+1) = AAA
What is the price of IVZ shares?

As of September 05, 2026, the stock is trading at USD 32.71 with a total of 3,470,192 shares traded. Over the past week, the price has changed by -1.80%, over one month by +6.53%, over three months by +22.23% and over the past year by +55.53%.

Current recommended Stop Loss: 30.30 (which is 7.4% or 2.6 ATR below the current price).

Is IVZ a buy, sell or hold?

has received a consensus analysts rating of 3.07. Therefore, it is recommended to hold IVZ.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 11
  • Sell: 0
  • StrongSell: 1

What are the forecasts/targets for the IVZ price?
Analysts Target Price 33.4 2%
(IVZ) - Fundamental Data Overview as of 31 August 2026
Market Cap USD = 14.5b (14.5b USD * 1.0 USD.USD)
P/E Forward = 12.0627
P/S = 2.1018
P/B = 1.4763
P/EG = 0.9008
Revenue TTM = 6.90b USD
EBIT TTM = -396.3m USD
EBITDA TTM = 1.49b USD
Long Term Debt = 9.27b USD (from longTermDebt, last quarter)
Short Term Debt = 66.6m USD (from shortTermDebt, last fiscal year)
Debt = 9.74b USD (corrected: LT Debt 9.27b + ST Debt 66.6m) + Leases 406.7m
Net Debt = 8.82b USD (calculated: Debt 9.74b - CCE 915.4m)
Enterprise Value = 23.3b USD (14.5b + Debt 9.74b - CCE 915.4m)
Interest Coverage Ratio = -4.10 (Ebit TTM -396.3m / Interest Expense TTM 96.6m)
EV/FCF = 11.87x (Enterprise Value 23.3b / FCF TTM 1.97b)
FCF Yield = 8.42% (FCF TTM 1.97b / Enterprise Value 23.3b)
FCF Margin = 28.47% (FCF TTM 1.97b / Revenue TTM 6.90b)
Net Margin = -0.93% (Net Income TTM -64.5m / Revenue TTM 6.90b)
Gross Margin = 67.42% ((Revenue TTM 6.90b - Cost of Revenue TTM 2.25b) / Revenue TTM)
Gross Margin QoQ = none% (prev 65.53%)
Tobins Q-Ratio = 0.85 (Enterprise Value 23.3b / Total Assets 27.5b)
Interest Expense / Debt = 0.99% (Interest Expense 96.6m / Debt 9.74b)
Taxrate = 25.58% (116.5m / 455.4m)
NOPAT = -294.9m (EBIT -396.3m * (1 - 25.58%)) [loss with tax shield]
Current Ratio = 0.71 (Total Current Assets 1.72b / Total Current Liabilities 2.43b)
Debt / Equity = 0.78 (Debt 9.74b / totalStockholderEquity, last quarter 12.5b)
Debt / EBITDA = 5.93 (Net Debt 8.82b / EBITDA 1.49b)
Debt / FCF = 4.49 (Net Debt 8.82b / FCF TTM 1.97b)
Total Stockholder Equity = 12.7b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.23% (Net Income -64.5m / Total Assets 27.5b)
RoE = -0.51% (Net Income TTM -64.5m / Total Stockholder Equity 12.7b)
RoCE = -1.80% (EBIT -396.3m / Capital Employed (Equity 12.7b + L.T.Debt 9.27b))
 RoIC = -1.19% (negative operating profit) (NOPAT -294.9m / Invested Capital 24.8b)
 WACC = 7.74% (E(14.5b)/V(24.2b) * Re(12.44%) + D(9.74b)/V(24.2b) * Rd(0.99%) * (1-Tc(0.26)))
Discount Rate = 12.44% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -35.08 | Cagr: 0.09%
[DCF] Terminal Value 77.97% ; FCFF base≈1.66b ; Y1≈1.90b ; Y5≈2.80b
[DCF] Fair Price = 75.36 (EV 42.1b - Net Debt 8.82b = Equity 33.3b / Shares 441.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 96.55 | EPS CAGR: 19.84% | SUE: 0.64 | # QB: 0
Revenue Correlation: 96.25 | Revenue CAGR: 6.53% | SUE: 0.84 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.74 | Chg30d=-2.62% | Revisions=+42% | Analysts=11
EPS current Year (2026-12-31): EPS=2.81 | Chg30d=+1.23% | Revisions=+80% | GrowthEPS=+38.3% | GrowthRev=+16.3%
EPS next Year (2027-12-31): EPS=3.26 | Chg30d=+2.00% | Revisions=+79% | GrowthEPS=+16.2% | GrowthRev=+8.8%
[Analyst] Revisions Ratio: +80% (up=30, down=2)